Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen and Johnson and Johnson dismiss anaemia drug risk

Amgen and Johnson and Johnson dismiss anaemia drug risk

27th February 2008

Amgen and Johnson & Johnson (J&J) have dismissed new study results that suggest their anaemia drugs raise the risk of death among cancer patients by around ten per cent.

The study reviewed previous clinical trial data and revealed that a statistically significance increase in the risk of death from the drugs, reports the New York Times.

Dr Charles L Bennett, lead author of the study and a professor at Northwestern University, indicated that the study also found a 57 per cent increase in the risk of blood clots in veins, a known-side effect of the drugs.

Responding to the study, Amgen’s executive vice-president for research and development Dr Roger Perlmutter suggested that it provided very little new information.

“What he observes is the risks that we’ve already talked about that are in the label,” he stated.

The study is published following a statement from the Food and Drug Administration that it is planning to convene an advisory committee next month to discuss the possibility of further restrictions on the use of Amgen’s Aranesp and J&J’s Procrit.

Earlier this month, Amgen and Takeda Pharmaceutical signed an exclusive collaboration agreement to work together on up to 13 clinical candidates from Amgen.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.